Lifesciences IT - 2011 YearbookSummaryGBI Research's research, 'Lifesciences IT - 2011 Yearbook" provides key data, information and analysis on Lifesciences \IT that is being implemented by pharmaceutical companies. GBI Research expects that information technology (IT) in the lifesciences industry will become a trendsetter, helping pharmaceutical companies mitigate current and evolving industry challenges. IT solutions utilized in the value chain of pharmaceutical companies help them to operate effectively and efficiently. GBI expects an increase in the adoption of IT by pharmaceutical companies looking to remain competitive in the market place. The Lifesciences industry is pressurized by various challenges such as declining Return on Investment (ROI) on R&D investments, entry of generics and layoffs. These factors are responsible for the lifesciences companies to invest in information technology solutions. Pharmaceutical companies have found that experimental techniques are costly, time-consuming, and involve the use of large numbers of animals for testing and are adapting to computerized combinatorial chemistry applications. Pharmaceutical Companies are increasingly adopting e-clinical trial solutions in the drug development phase. Cutting down clinical trial cost is the driving motivation for the adoption of e-clinical trial solutions. Services offered by IT companies in clinical data management are costly but have been proved to save cost for the companies in the long run. CTMS and EDC will attract the highest investments in the future followed by data mining, electronic submission tools and RFID. Outsourcing helps a pharmaceutical company to reduce costs by 30-35% and this is one of the main reasons why pharmaceutical companies outsource non-core R&D operational work to IT companies. When selecting a country to outsource clinical data management work, building the required competencies to tackle client requirements has gained a higher importance than the cost advantage it provides. The predictive analytics helps a company view beyond the sales volume in to real time prescribing patterns, as a behavior of continuum. This also helps the company to follow the evolving niche buster model. Many pharmaceutical companies have increased satisfaction levels from their customers in 2008. In 2004, 50% of the physicians were satisfied on the current number of calls. However, satisfaction levels have increased in 2008 with more than 57% of the physicians in the US satisfied with the current number of calls. The increase in satisfaction levels was directly proportional to the decrease of sales force in the US. It is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research's team of industry experts.ScopeThe scope of this report includes - - Analysis of the leading segments in the Lifesciences IT market - Key drivers and barriers that have a significant impact on the Lifesciences IT market. - Competitive benchmarking of leading companies in the market. - Key M&A activities and strategic partnership deals that have taken place in 2009.- Inputs for customized IT solution based on business situation.Reasons to buyThe report will enhance your decision making capability. It will provide you with - - Align your product portfolio to the markets with high growth potential.- Develop market-entry and market expansion strategies by identifying the leading segments poised for strong growth.- Device better strategies through the understanding of key drivers and barriers in the market.- Develop key strategic initiatives by understanding the key focus of leading companies.- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
Phase Forward provides clinical trial software and services that help customers manage clinical data digitally rather than with paper. While they face competition, Phase Forward has significant market share in a growing industry. However, increased government regulation and industry consolidation may slow future growth. If a competitor like Oracle acquired Medidata, Phase Forward's largest rival, it could negatively impact Phase Forward's competitive position. For these reasons, the document recommends caution in investing in Phase Forward.
Putting Together the Pieces: Supply Chain Analytics - 2 SEP 2017Lora Cecere
RESEARCH OVERVIEW:
Report Details: This report is the result of six months of studying the emerging supply chain analytics technology market. This report is based on qualitative research completed in the period of January-July 2016. In this research effort, we interviewed thirty-five technology analytics providers to understand their solutions. This was followed by interviews with thirty innovative supply chain leaders. To support this research and take it one step further, we augment these qualitative insights with quantitative survey analysis collected in preparation for the Supply Chain Insights Global Summit. In this research, we share insights on the importance of supply chain analytics in Supply Chain 2030 strategies. Here we share these findings.
Objective: To understand the changing role of supply chain analytics in supply chain strategy.
Highlight: With the changing face of supply chain analytics companies have greater opportunities to drive insights and gain competitive advantage. This report is designed to help companies bridge traditional thinking on supply chain analytics while embracing emerging technologies.
Executive Summary
Supply chains are drowning in data, but are low on insights. While the cost of computing memory was once a barrier to executing an analytics strategy, this is no longer the case. The largest barrier is the understanding of new forms of analytics.
Historically, the term supply chain analytics was used to describe reporting. This is no longer the case. Today there are more options and capabilities for supply chain analytics. There is a proliferation of new technologies flooding the market.
Ironically, despite the explosion of options as shown in Figure 1, the supply chain operating team is more conservative. It is a skewed distribution. When it comes to decision support, the number of late adopters outnumber the early adopters three to one. The lack of early adopters, the rapid rate of change, and the conventional architectural definitions (primarily focused on Enterprise Resource Planning or ERP-based architectures) are barriers to the adoption of new forms of supply chain analytics.
Driving Digital Supply Chain Transformation - A Handbook - 23 MAY 2017Lora Cecere
Insights on driving a digital transformation based on research on new technologies, advisory work with clients, and quantitative research projects. This is a short handbook to help companies get started on their journey to define the digital supply chain.
Stc384 team phoenix scenario analysis exec summary approval from ccmClaudia Chittim
The document provides an executive summary of a scenario analysis for a cancer detection device that is in early development. It discusses the current medical device industry landscape and various factors that could impact the industry in the future. The analysis identifies key variables like FDA approval process and adoption rates. Several potential scenarios are constructed based on combinations of assumptions for each variable. Scenario 9 is identified as optimal for the cancer detection device, involving a differentiated strategy, focus on a niche market, and a proprietary technology that integrates with existing platforms.
Technology is disrupting the process behind drug development. Growing realization that current clinical trial strategies are not sustainable or feasible means one thing - change. But, where do pharmaceutical companies go from here? An integrated clinical trial ecosystem will arise through leveraging emerging business technologies. But, are companies prepared to take advantage?
This document discusses precompetitive collaborations in the pharmaceutical industry. It defines precompetitive as referring to standards, data, or processes that are common across an industry and provide no competitive advantage. The document outlines a precompetitive mission statement to foster collaborations between organizations to develop standards, identify partnerships, and transfer technology. It also describes current working groups focused on areas like biomarkers, clinical trial design, and data standards.
This document discusses Optum's leadership in the clinical documentation and coding market. It notes the challenges healthcare providers face with transitioning to value-based reimbursement models and increased coding complexity. Optum's clinical documentation improvement and computer-assisted coding solutions help providers improve coding accuracy and efficiency to maximize reimbursement. The solutions integrate natural language processing technology to automate coding tasks. Customers see benefits such as increased productivity and standardized coding processes. As a result, Optum has experienced significant growth and an increasing market share in the clinical documentation and coding space.
Phase Forward provides clinical trial software and services that help customers manage clinical data digitally rather than with paper. While they face competition, Phase Forward has significant market share in a growing industry. However, increased government regulation and industry consolidation may slow future growth. If a competitor like Oracle acquired Medidata, Phase Forward's largest rival, it could negatively impact Phase Forward's competitive position. For these reasons, the document recommends caution in investing in Phase Forward.
Putting Together the Pieces: Supply Chain Analytics - 2 SEP 2017Lora Cecere
RESEARCH OVERVIEW:
Report Details: This report is the result of six months of studying the emerging supply chain analytics technology market. This report is based on qualitative research completed in the period of January-July 2016. In this research effort, we interviewed thirty-five technology analytics providers to understand their solutions. This was followed by interviews with thirty innovative supply chain leaders. To support this research and take it one step further, we augment these qualitative insights with quantitative survey analysis collected in preparation for the Supply Chain Insights Global Summit. In this research, we share insights on the importance of supply chain analytics in Supply Chain 2030 strategies. Here we share these findings.
Objective: To understand the changing role of supply chain analytics in supply chain strategy.
Highlight: With the changing face of supply chain analytics companies have greater opportunities to drive insights and gain competitive advantage. This report is designed to help companies bridge traditional thinking on supply chain analytics while embracing emerging technologies.
Executive Summary
Supply chains are drowning in data, but are low on insights. While the cost of computing memory was once a barrier to executing an analytics strategy, this is no longer the case. The largest barrier is the understanding of new forms of analytics.
Historically, the term supply chain analytics was used to describe reporting. This is no longer the case. Today there are more options and capabilities for supply chain analytics. There is a proliferation of new technologies flooding the market.
Ironically, despite the explosion of options as shown in Figure 1, the supply chain operating team is more conservative. It is a skewed distribution. When it comes to decision support, the number of late adopters outnumber the early adopters three to one. The lack of early adopters, the rapid rate of change, and the conventional architectural definitions (primarily focused on Enterprise Resource Planning or ERP-based architectures) are barriers to the adoption of new forms of supply chain analytics.
Driving Digital Supply Chain Transformation - A Handbook - 23 MAY 2017Lora Cecere
Insights on driving a digital transformation based on research on new technologies, advisory work with clients, and quantitative research projects. This is a short handbook to help companies get started on their journey to define the digital supply chain.
Stc384 team phoenix scenario analysis exec summary approval from ccmClaudia Chittim
The document provides an executive summary of a scenario analysis for a cancer detection device that is in early development. It discusses the current medical device industry landscape and various factors that could impact the industry in the future. The analysis identifies key variables like FDA approval process and adoption rates. Several potential scenarios are constructed based on combinations of assumptions for each variable. Scenario 9 is identified as optimal for the cancer detection device, involving a differentiated strategy, focus on a niche market, and a proprietary technology that integrates with existing platforms.
Technology is disrupting the process behind drug development. Growing realization that current clinical trial strategies are not sustainable or feasible means one thing - change. But, where do pharmaceutical companies go from here? An integrated clinical trial ecosystem will arise through leveraging emerging business technologies. But, are companies prepared to take advantage?
This document discusses precompetitive collaborations in the pharmaceutical industry. It defines precompetitive as referring to standards, data, or processes that are common across an industry and provide no competitive advantage. The document outlines a precompetitive mission statement to foster collaborations between organizations to develop standards, identify partnerships, and transfer technology. It also describes current working groups focused on areas like biomarkers, clinical trial design, and data standards.
This document discusses Optum's leadership in the clinical documentation and coding market. It notes the challenges healthcare providers face with transitioning to value-based reimbursement models and increased coding complexity. Optum's clinical documentation improvement and computer-assisted coding solutions help providers improve coding accuracy and efficiency to maximize reimbursement. The solutions integrate natural language processing technology to automate coding tasks. Customers see benefits such as increased productivity and standardized coding processes. As a result, Optum has experienced significant growth and an increasing market share in the clinical documentation and coding space.
Biotechnology: Industry position survey 2012 GT AustraliaGrant Thornton
The biotechnology industry position survey provides an annual snapshot of the industry's views on key issues. The key findings were:
1) Sentiment in the industry remains positive, with 82% of respondents expecting business growth in the coming year and 68% characterizing 2011 as a good year.
2) Most companies plan to increase staffing levels, primarily in sales/marketing and scientific roles.
3) Despite 54% raising capital in 2011, funding remains a challenge with 34% having less than 12 months of cash.
4) The majority see the new R&D tax incentive as positively impacting their business, though over half have not sought advice on it.
Kareo is recognized for its innovative cloud-based healthcare IT solutions for ambulatory physician practices in the United States. It offers clinical, financial, and patient engagement solutions that help practices improve productivity and optimize reimbursement. Key innovations include Kareo Telemedicine, which provides secure video consultations, and ensures reimbursement for telehealth visits. Kareo's modular EHR solution can be customized and deployed quickly. Its integrated solutions are interoperable and help streamline operations while establishing cost competitiveness compared to separate clinical and financial systems. Kareo provides diverse solutions to address challenges around managing patient payments from various payers.
Digital Manufacturing Study - 2013-2014 - Summary ChartsLora Cecere
This document summarizes the findings of a study on digital manufacturing. It discusses topics like manufacturing networks, digital strategies, and key metrics. The study found that one-third of respondents have or plan a digital strategy. For process industries, over a quarter already use manufacturing execution systems and nearly a third plan to use mobility in plants. Discrete industries expect an 81% increase in 3D printing importance and over a third already use it for production. Supply chain organizations were also discussed.
The document summarizes the results of the sixth annual Deloitte Technology Fast 50 India program, which recognizes the fastest growing technology companies in India based on revenue growth over three years. It provides details on the top three winners, insights into trends in the technology sector in India, and analysis of growth patterns among companies of different sizes and sectors. The top winner had average growth of 1765% and was in the networking industry, while other top companies were in media/creative services and tech support. Overall, software companies made up the largest portion of the top 50 but their dominance decreased from previous years.
BJC HealthCare and Medtronic won awards for innovative supply chain initiatives in healthcare. BJC partnered with Cardinal Health and Cook Medical to centralize medical device inventory, providing visibility and reducing costs. Medtronic developed a program to manage hospital cath labs end-to-end, creating cost savings and improved outcomes for providers. Both winners demonstrated collaboration across the healthcare value chain can improve efficiency, lower costs and enhance patient care.
The document discusses mergers and acquisitions and their impact on innovation. It provides an overview of different types of mergers, how they are regulated, and potential motivations for mergers. The research question examines whether the stock market reactions of acquiring companies, target companies, and their rivals can predict changes in research and development intensity after mergers. The methodology uses an event study approach analyzing 212 mergers between 1990-2014. The results found that acquiring companies often increased R&D intensity despite negative stock returns, while rivals typically reacted negatively to mergers that increased the acquirer's R&D. In conclusion, the stock reactions of companies and rivals can indicate whether a merger is likely to increase post-merger R&D intensity.
Tego, Inc. was awarded the 2016 New Product Innovation Award for its asset intelligence platform solution for the healthcare industry. The solution addresses challenges in healthcare supply chain management through a 3-layered system including intelligent chips, tags, and software. This allows any physical asset to be digitized and remotely tracked. Tego's solution helps reduce costs for hospitals through improved asset utilization and control. It also enables compliance with regulations through embedded data storage on devices. The solution represents an innovative approach to smart asset management through its design, data security, and cost-effective platform model.
This document provides an overview of the science and business of drug discovery and development. It discusses the histories of large pharmaceutical companies and biotech startups. The current business landscape is defined by mergers and acquisitions as companies strive for efficiency. The scientific landscape is constrained by a limited number of known drug targets. Future trends may include increased collaboration between industry and academia to improve productivity and develop pre-competitive standards.
The global health and life sciences market is large, complex and fragmented. While data flows freely, an information gap has formed. Pfizer has made investments in companies like Private Access, Keas and Acacia Living that focus on personalized healthcare, health and wellness, and empowering consumers. Pfizer also looks to form partnerships to solve complex problems through multi-stakeholder collaboration.
This document summarizes a presentation given by Dr. Robert Boorstein on drivers of change in the laboratory market. Five key trends are discussed: laboratory consolidation, growth of central laboratories vs point-of-care testing, new delivery models, new technologies, and increased competition across sectors. Laboratory consolidation is driven by cost reductions and allows for standardization but may shift market power from sellers to buyers. Point-of-care testing is growing rapidly but poses challenges to quality control. New national laboratory companies are emerging focused on unique branded products.
MedTech Quality in the Age of Big Data - Are you ready?Naveen Agarwal
Technology is creating a big change in the Medical industry. This presentation provides an overview of the changing industry landscape and how Quality/Regulatory professionals can prepare for the age of Big Data.
Global Trends in Medical Device and Diagnostic OEM Strategy and Implications ...Tony Freeman
Manning Advisors is pleased to announce the publication of its 2017 Global Trends in Medical Device and Diagnostic OEM Strategy and Implications for the Supply Chain. As in past years we looked at the major issues facing medical device OEMs and how those issues drive their relationship with their suppliers.
Our findings this year include:
Medical Device OEMs focusing on improved organic growth
2016 saw major OEMs relying heavily on acquisitions to improve revenues
OEMs see the eventual end of needle-moving acquisitions and are focusing on how to accelerate organic growth
Fee-for-value reimbursement and growing use of informatics are leading to redesign of product suites
The Supply Chain is consolidating around fewer, larger players
The supply chain is also consolidating via acquisitions
OEMs are embracing risk reduction by working with larger supply chain partners
The new threat to existing supply chain companies is the penetration of the market by giant global contract manufacturers like Flextronics and Celestica
Opportunity exists for smaller, nimble players who can assist OEMs in bring product to market more quickly
Opportunity also exists for specialized manufacturers
Feel free to contact me to discuss the issues or to arrange for an onsite presentation to your Board or management team. I look forward to an intriguing discussion.
You may reach me at tfreeman@manningadvisors.com or at (917) 868-0772 directly.
Best regards,
Tony Freeman, Managing Director
Manning Advisors LLC
90 Park Avenue, 17th Floor
New York, NY 10016
Emerging Trends In Medical Device ManufacturingEWI
To continue a trajectory of steady growth, the global medical device industry must adapt to the dynamic changes disrupting the healthcare landscape. An aging population, a push for more personalized treatment, and the increasing availability of healthcare are some of the factors driving new markets and an expanding consumer base. In addition, regulatory scrutiny and federal initiatives like the medical device excise tax have levied extra pressure on R&D budgets.
Pistoia Alliance US Conference 2015 - 1.1.2 Innovation in Pharma - Chris WallerPistoia Alliance
The document discusses innovation through platforms and modeling at the "edge." It describes how platforms can create and capture value by enabling new applications and business outcomes. Specifically, it outlines Merck's plans to develop a Scientific Modeling Platform to integrate data and predictive models across research, development, and medical domains. This platform would support collaborative modeling efforts and drive innovation by providing predictive insights earlier in the drug development process. Ultimately, the platform aims to transform drug discovery and development at Merck through increased use of analytics, data-driven decision making, and more successful projects.
McKinsey Sağlık Tedarik Zinciriyle, FMCG Tedarik Zinciri karşılaştırıyor. Sağlık Tedarik Zincirindeki iyileştirme fırsatına ve toplumsal boyutuna dikkat çekiyor.
This survey summarizes the responses of 52 biotechnology companies regarding business sentiment, financing, employment, and government policy issues. Key findings include:
- Business sentiment is optimistic, with 75% expecting business growth in 2011. However, only 13% said the operating environment supports industry growth.
- Over half of respondents plan to raise capital in 2011, with 23% having less than 12 months of funding. Access to capital is a major challenge.
- Delays to the R&D Tax Credit legislation were the most concerning federal policy issue, identified by 61% of respondents.
- 76% said state government support for biotechnology was the most important state-level issue.
Flex is a global contract manufacturer that was named Company of the Year for Medical Device Design and Manufacturing Solutions by Frost & Sullivan in 2019. Flex partners with healthcare companies to design and manufacture innovative medical devices by leveraging its expertise in electronics and manufacturing. Flex helps companies bring products to market faster through its "sketch-to-scale" approach and ensures products remain technologically advanced. Flex also developed BrightInsight, an FDA and HIPAA-compliant platform that uses AI to integrate patient data and provide insights to support digital health.
How to Create a Big Data Culture in PharmaChris Waller
A talk presented at the Big Data and Analytics conference in Boston on January 28, 2014. Emphasis on data and information sharing cultures in companies.
IT Outsourcing (ITO) in the Life Sciences Industry - Service Provider LandscapeEverest Group
This report provides a comprehensive assessment of the service provider landscape for IT outsourcing (ITO) services in the life sciences industry. It maps 14 leading service providers on the Everest Group PEAK Matrix and includes detailed profiles of these service providers. This evaluation categorizes the service providers into Leaders, Major Contenders, and Emerging Players. It also identifies top three service providers as Star Performers, based on their year on year movement on the Matrix
China Laboratory Informatics Market Forecast 2020|MarkNtel AdvisorsMarkNtel Advisors
China Laboratory Informatics Market- By Product Type (Electronic Lab Notebooks (ELNs), Laboratory Information Management Systems (LIMS), Chromatography Data Systems (CDS), Electronic Data Capture (EDC) & Clinical Data Management Systems, Laboratory Execution Systems (LES), Enterprise Content Management Systems (ECM), Scientific Data Management Systems (SDMS)), By Components (Service, Software), By Industry (Pharma and Biotechnology, Biobanks & Bio Repositories, Molecular Diagnostics & Clinical Research Labs, Contract Service Organization, Academia, Food and Beverage, Chemical Industry, Petrochemical Refinery & Oil and Gas Industry), By Deployment Model (Remote Hosting, On-Premise Model, Cloud-Based Model), By Competitors (Lab Vantage, LabLynx, Autoscribe, Perkin Elmer, Thermofisher Scientific, Beijing LabWare and Sci & Tech Co., Agilent Technologies (Beijing), Abbott Laboratories, Waters Corporation, McKesson Corporation)
Reports URL- https://www.marknteladvisors.com/research-library/china-laboratory-informatics.html
Biotechnology: Industry position survey 2012 GT AustraliaGrant Thornton
The biotechnology industry position survey provides an annual snapshot of the industry's views on key issues. The key findings were:
1) Sentiment in the industry remains positive, with 82% of respondents expecting business growth in the coming year and 68% characterizing 2011 as a good year.
2) Most companies plan to increase staffing levels, primarily in sales/marketing and scientific roles.
3) Despite 54% raising capital in 2011, funding remains a challenge with 34% having less than 12 months of cash.
4) The majority see the new R&D tax incentive as positively impacting their business, though over half have not sought advice on it.
Kareo is recognized for its innovative cloud-based healthcare IT solutions for ambulatory physician practices in the United States. It offers clinical, financial, and patient engagement solutions that help practices improve productivity and optimize reimbursement. Key innovations include Kareo Telemedicine, which provides secure video consultations, and ensures reimbursement for telehealth visits. Kareo's modular EHR solution can be customized and deployed quickly. Its integrated solutions are interoperable and help streamline operations while establishing cost competitiveness compared to separate clinical and financial systems. Kareo provides diverse solutions to address challenges around managing patient payments from various payers.
Digital Manufacturing Study - 2013-2014 - Summary ChartsLora Cecere
This document summarizes the findings of a study on digital manufacturing. It discusses topics like manufacturing networks, digital strategies, and key metrics. The study found that one-third of respondents have or plan a digital strategy. For process industries, over a quarter already use manufacturing execution systems and nearly a third plan to use mobility in plants. Discrete industries expect an 81% increase in 3D printing importance and over a third already use it for production. Supply chain organizations were also discussed.
The document summarizes the results of the sixth annual Deloitte Technology Fast 50 India program, which recognizes the fastest growing technology companies in India based on revenue growth over three years. It provides details on the top three winners, insights into trends in the technology sector in India, and analysis of growth patterns among companies of different sizes and sectors. The top winner had average growth of 1765% and was in the networking industry, while other top companies were in media/creative services and tech support. Overall, software companies made up the largest portion of the top 50 but their dominance decreased from previous years.
BJC HealthCare and Medtronic won awards for innovative supply chain initiatives in healthcare. BJC partnered with Cardinal Health and Cook Medical to centralize medical device inventory, providing visibility and reducing costs. Medtronic developed a program to manage hospital cath labs end-to-end, creating cost savings and improved outcomes for providers. Both winners demonstrated collaboration across the healthcare value chain can improve efficiency, lower costs and enhance patient care.
The document discusses mergers and acquisitions and their impact on innovation. It provides an overview of different types of mergers, how they are regulated, and potential motivations for mergers. The research question examines whether the stock market reactions of acquiring companies, target companies, and their rivals can predict changes in research and development intensity after mergers. The methodology uses an event study approach analyzing 212 mergers between 1990-2014. The results found that acquiring companies often increased R&D intensity despite negative stock returns, while rivals typically reacted negatively to mergers that increased the acquirer's R&D. In conclusion, the stock reactions of companies and rivals can indicate whether a merger is likely to increase post-merger R&D intensity.
Tego, Inc. was awarded the 2016 New Product Innovation Award for its asset intelligence platform solution for the healthcare industry. The solution addresses challenges in healthcare supply chain management through a 3-layered system including intelligent chips, tags, and software. This allows any physical asset to be digitized and remotely tracked. Tego's solution helps reduce costs for hospitals through improved asset utilization and control. It also enables compliance with regulations through embedded data storage on devices. The solution represents an innovative approach to smart asset management through its design, data security, and cost-effective platform model.
This document provides an overview of the science and business of drug discovery and development. It discusses the histories of large pharmaceutical companies and biotech startups. The current business landscape is defined by mergers and acquisitions as companies strive for efficiency. The scientific landscape is constrained by a limited number of known drug targets. Future trends may include increased collaboration between industry and academia to improve productivity and develop pre-competitive standards.
The global health and life sciences market is large, complex and fragmented. While data flows freely, an information gap has formed. Pfizer has made investments in companies like Private Access, Keas and Acacia Living that focus on personalized healthcare, health and wellness, and empowering consumers. Pfizer also looks to form partnerships to solve complex problems through multi-stakeholder collaboration.
This document summarizes a presentation given by Dr. Robert Boorstein on drivers of change in the laboratory market. Five key trends are discussed: laboratory consolidation, growth of central laboratories vs point-of-care testing, new delivery models, new technologies, and increased competition across sectors. Laboratory consolidation is driven by cost reductions and allows for standardization but may shift market power from sellers to buyers. Point-of-care testing is growing rapidly but poses challenges to quality control. New national laboratory companies are emerging focused on unique branded products.
MedTech Quality in the Age of Big Data - Are you ready?Naveen Agarwal
Technology is creating a big change in the Medical industry. This presentation provides an overview of the changing industry landscape and how Quality/Regulatory professionals can prepare for the age of Big Data.
Global Trends in Medical Device and Diagnostic OEM Strategy and Implications ...Tony Freeman
Manning Advisors is pleased to announce the publication of its 2017 Global Trends in Medical Device and Diagnostic OEM Strategy and Implications for the Supply Chain. As in past years we looked at the major issues facing medical device OEMs and how those issues drive their relationship with their suppliers.
Our findings this year include:
Medical Device OEMs focusing on improved organic growth
2016 saw major OEMs relying heavily on acquisitions to improve revenues
OEMs see the eventual end of needle-moving acquisitions and are focusing on how to accelerate organic growth
Fee-for-value reimbursement and growing use of informatics are leading to redesign of product suites
The Supply Chain is consolidating around fewer, larger players
The supply chain is also consolidating via acquisitions
OEMs are embracing risk reduction by working with larger supply chain partners
The new threat to existing supply chain companies is the penetration of the market by giant global contract manufacturers like Flextronics and Celestica
Opportunity exists for smaller, nimble players who can assist OEMs in bring product to market more quickly
Opportunity also exists for specialized manufacturers
Feel free to contact me to discuss the issues or to arrange for an onsite presentation to your Board or management team. I look forward to an intriguing discussion.
You may reach me at tfreeman@manningadvisors.com or at (917) 868-0772 directly.
Best regards,
Tony Freeman, Managing Director
Manning Advisors LLC
90 Park Avenue, 17th Floor
New York, NY 10016
Emerging Trends In Medical Device ManufacturingEWI
To continue a trajectory of steady growth, the global medical device industry must adapt to the dynamic changes disrupting the healthcare landscape. An aging population, a push for more personalized treatment, and the increasing availability of healthcare are some of the factors driving new markets and an expanding consumer base. In addition, regulatory scrutiny and federal initiatives like the medical device excise tax have levied extra pressure on R&D budgets.
Pistoia Alliance US Conference 2015 - 1.1.2 Innovation in Pharma - Chris WallerPistoia Alliance
The document discusses innovation through platforms and modeling at the "edge." It describes how platforms can create and capture value by enabling new applications and business outcomes. Specifically, it outlines Merck's plans to develop a Scientific Modeling Platform to integrate data and predictive models across research, development, and medical domains. This platform would support collaborative modeling efforts and drive innovation by providing predictive insights earlier in the drug development process. Ultimately, the platform aims to transform drug discovery and development at Merck through increased use of analytics, data-driven decision making, and more successful projects.
McKinsey Sağlık Tedarik Zinciriyle, FMCG Tedarik Zinciri karşılaştırıyor. Sağlık Tedarik Zincirindeki iyileştirme fırsatına ve toplumsal boyutuna dikkat çekiyor.
This survey summarizes the responses of 52 biotechnology companies regarding business sentiment, financing, employment, and government policy issues. Key findings include:
- Business sentiment is optimistic, with 75% expecting business growth in 2011. However, only 13% said the operating environment supports industry growth.
- Over half of respondents plan to raise capital in 2011, with 23% having less than 12 months of funding. Access to capital is a major challenge.
- Delays to the R&D Tax Credit legislation were the most concerning federal policy issue, identified by 61% of respondents.
- 76% said state government support for biotechnology was the most important state-level issue.
Flex is a global contract manufacturer that was named Company of the Year for Medical Device Design and Manufacturing Solutions by Frost & Sullivan in 2019. Flex partners with healthcare companies to design and manufacture innovative medical devices by leveraging its expertise in electronics and manufacturing. Flex helps companies bring products to market faster through its "sketch-to-scale" approach and ensures products remain technologically advanced. Flex also developed BrightInsight, an FDA and HIPAA-compliant platform that uses AI to integrate patient data and provide insights to support digital health.
How to Create a Big Data Culture in PharmaChris Waller
A talk presented at the Big Data and Analytics conference in Boston on January 28, 2014. Emphasis on data and information sharing cultures in companies.
IT Outsourcing (ITO) in the Life Sciences Industry - Service Provider LandscapeEverest Group
This report provides a comprehensive assessment of the service provider landscape for IT outsourcing (ITO) services in the life sciences industry. It maps 14 leading service providers on the Everest Group PEAK Matrix and includes detailed profiles of these service providers. This evaluation categorizes the service providers into Leaders, Major Contenders, and Emerging Players. It also identifies top three service providers as Star Performers, based on their year on year movement on the Matrix
China Laboratory Informatics Market Forecast 2020|MarkNtel AdvisorsMarkNtel Advisors
China Laboratory Informatics Market- By Product Type (Electronic Lab Notebooks (ELNs), Laboratory Information Management Systems (LIMS), Chromatography Data Systems (CDS), Electronic Data Capture (EDC) & Clinical Data Management Systems, Laboratory Execution Systems (LES), Enterprise Content Management Systems (ECM), Scientific Data Management Systems (SDMS)), By Components (Service, Software), By Industry (Pharma and Biotechnology, Biobanks & Bio Repositories, Molecular Diagnostics & Clinical Research Labs, Contract Service Organization, Academia, Food and Beverage, Chemical Industry, Petrochemical Refinery & Oil and Gas Industry), By Deployment Model (Remote Hosting, On-Premise Model, Cloud-Based Model), By Competitors (Lab Vantage, LabLynx, Autoscribe, Perkin Elmer, Thermofisher Scientific, Beijing LabWare and Sci & Tech Co., Agilent Technologies (Beijing), Abbott Laboratories, Waters Corporation, McKesson Corporation)
Reports URL- https://www.marknteladvisors.com/research-library/china-laboratory-informatics.html
China Laboratory Informatics Market Trends, Growth and Forecast AdrenaSharma
The China Laboratory Informatics Market which was in its embryonic stage in 2019, is majorly driven by the healthcare & life sciences institutions. While its penetration in other industries like chemicals, petrochemicals, food & beverages, environmental testing, etc., remains infinitesimal with minute scope for adoption in the coming years.
Madison Park Group Life Sciences Software Market Update H2 2018Madison Park Group
The document provides an update on the life sciences software market in the second half of 2018. Key points include:
1) Continued M&A activity in the clinical trials software space, with many assets moving between private equity firms.
2) Emerging technologies aim to optimize clinical trials and decision making through integration of software, data analytics, and real world evidence.
3) Regulations like SEND and the EU Clinical Trials Regulation are driving standardization and may increase spend on compliant software and services.
We are pleased to present our review of the life sciences software market for the first half of 2019.
Madison Park Group is a unique investment banking firm that takes a "strategy first" approach to advising software companies. Our partners have developed and advised numerous successful companies as operators, investors and investment bankers.
Rohan Khanna and Jonathan Adler spearhead the firm's efforts in the space.
Beyond Bioprocessing 4.0: The Convergence of IT, OT and Processing Technolog...Merck Life Sciences
Watch the interactive on-demand webinar here: https://bit.ly/2G8KSMu
The cost to develop and manufacture monoclonal antibodies has been highlighted as a substantial hurdle towards the widespread availability of these effective therapies for patients. Facility costs, utilization and labor are key contributing factors to the overall cost of these critical medicines. A proven method to increase utilization of a facility, increase process and quality robustness and lower overall costs of manufacturing is through the automation of a manufacturing process. The transformative impact that digital technologies have had on other industries’ manufacturing operations through IT and OT can be applied to the evolution happening in biopharma today. Examples of commonly used unit operations such as bioreactor, mixing and chromatography will be presented to illustrate incremental improvements that can be achieved today, and what the future looks like with the convergence of Operational Technology (OT), Information Technology (IT) and existing processing technologies.
In this webinar, you will learn:
- Incremental improvements that can be achieved today using process automation
- Practical examples of commonly used operations to illustrate the impact of automation
- How the automated facility will look like in the future
Beyond Bioprocessing 4.0: The Convergence of IT, OT and Processing Technolog...MilliporeSigma
This document discusses the convergence of IT, OT and processing technologies in bioprocessing, also known as Bioprocessing 4.0. It outlines key market trends driving the industry towards continuous manufacturing like market growth, cost pressures and new product classes. The presentation defines Industry 4.0 and how its principles of interconnection, transparency, decentralized decisions and technical assistance apply to bioprocessing. Technologies that will enable Bioprocessing 4.0 like single use systems, process analytics and intensified unit operations are presented. A vision for the future "Facility of the Future" is described that will be continuous, sterile, predictive and autonomous through digital transformation.
Japan Laboratory Informatics Market PPT: Growth, Outlook, Demand, Keyplayer A...IMARC Group
The Japan laboratory informatics market size is projected to exhibit a growth rate (CAGR) of 5.30% during 2024-2032.
More Info:- https://www.imarcgroup.com/japan-laboratory-informatics-market
Practice Management System Market Share and Size, 2018 to 2024Signitech
The global practice management system market size was valued at USD 6.9 billion in 2015. The industry is majorly driven by its competence to bring efficiency in healthcare delivery.
Real-Time Locating System (RTLS) Market – Global Forecast to 2024infoholicresearch-llp
The document provides an overview and market analysis of the global real-time locating systems (RTLS) market. It discusses key growth drivers such as the increasing focus on optimizing operational performance across industries. The report also examines market trends, including the growing adoption of analytics and cloud-based IoT solutions. Additionally, it analyzes the RTLS market by technology, components, industry verticals, and regions from 2018-2024.
The survey of 56 European enterprises found that while IT governance and service delivery frameworks were widely adopted, the benefits realized often fell short of expectations. For IT governance frameworks like COBIT, improved processes and reduced risk were expected but benefits were modest. Service delivery frameworks like ITIL had higher adoption rates and usage maturity levels. However, expected benefits like better service delivery and faster solution delivery did not fully materialize. Overall, frameworks provided value through improved organization and management information, but quantifying benefits with metrics remained a challenge.
Global LED Driver IC Market for Display & Lighting Applications (2010 ' 2015)ReportLinker.com
Report DescriptionThe Global LED driver IC market is estimated to grow from $1,119.0 million in 2010 to $4,424.0 million in 2015, at an estimated CAGR of 31.6% from 2010 to 2015. Initiatives taken by the government to phase out demand for incandescent bulbs in lieu of high quality picture images, power efficient lighting offered by LED have increased the deployment and usage of LED driver IC in a range of applications such as displays and lighting.Amongst these two applications, the LED driver IC market for lighting applications is expected to grow with a relatively high CAGR of 46.5% from 2010 to 2015. Display application accounted for the largest share; i.e. 80% of the overall the LED driver IC market generating $895.2 million in 2010 and is expected to generate $2,914.0 million in 2015 with a CAGR of 26.6% for the same period.Scope of the reportThis research report categorizes the global LED driver IC market on the basis of different applications and countries; forecasting revenues, and analyzing trends in each of the smart home applications.On the basis of applicationsApplications such as display and lightings are covered in the report.On the basis of geographyNorth America, Europe, Asia-Pacific (APAC), and ROW (Rest of World) are covered in the report.Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables for covering the sub-segments and micro-markets. In addition, the report provides more than 24 company profiles covering all the sub-segments.What makes our reports unique'We provide the longest market segmentation chain in this industry.We provide 10% customization. Our customization will ensure that they necessarily get the market intelligence they are looking for and we get a loyal customer.We conduct detailed market positioning, product positioning, and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.Comprehensive market analysis is carried out for the following sectors:Pharmaceuticals, Medical Devices, Biotechnology, Semiconductor and Electronics, Energy and Power Supplies, Food and Beverages, Chemicals, Advanced Materials, Industrial Automation, and Telecom and IT. We also analyze retailers and super-retailers, technology providers, and research and development (R&D) companies.Key questions answeredWhich are the high-growth segments/cash cows and how is the market segmented in terms of applications and materials'What are market estimates and forecasts; which markets are doing well and which are not'Where are the gaps and opportunities; what is driving the market'Which are the key playing fields' Which are the winning edge imperatives'How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines' Who is doing what'Powerful research and analysisThe analysts working with MarketsandMarkets come from renowned publishing and market research firms, globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world. We, at MarketsandMarkets, are inspired to help our clients grow by providing qualitative business insights with our huge market intelligence repository.
Madison Park Group - Life Sciences Software M&A Market Update - H1 2018Madison Park Group
We are pleased to present our review of the life sciences software market for the first half of 2018.
Madison Park Group is a unique investment banking firm that takes a "strategy first" approach to advising software companies. Our partners have developed and advised numerous successful companies as operators, investors and investment bankers.
Rohan Khanna and Jon Adler spearhead the firm's efforts in the life sciences software market.
Has MES Reached Maturity in the Pharmaceutical & Medical Devices Industry...? Chary Kandukuri
This document discusses the maturity and adoption of Manufacturing Execution Systems (MES) in the pharmaceutical industry. It finds that MES has matured positively over the past 16+ years and is becoming a recognized best practice. A survey found that 47% of respondents had deployed electronic MES in manufacturing facilities, though only 31% had fully paperless solutions. The primary drivers for MES adoption were improving quality (39%) and production (41%), which together accounted for almost 80% of reasons. MES provides benefits like reduced costs, improved production capacity, and better financial costing. Regulatory agencies also view MES positively as helping ensure quality and risk mitigation.
China Patient Monitoring Market Outlook to 2018 - Fetal Monitors, Multiparame...ReportsnReports
This report provides an analysis of the patient monitoring market in China, including market segmentation, revenue forecasts, volume forecasts and average pricing from 2004-2018 for major product categories. It also examines company market shares and distribution channels. The 166-page report contains detailed data tables, profiles of key companies, and was published in September 2012 with a single user license price of $2,500.
This document summarizes a webinar on streamlining data management for clinical trials. The webinar covered the need for streamlined approaches given rising drug development costs. It discussed areas for improving efficiencies, including using standards, a parallel approach, identifying key reviewers, and tailoring processes based on trial type (e.g. a "Premier Express" approach for small phase 1 trials). An example case study showed how streamlining tasks and performing work in parallel reduced timelines for developing case report forms, annotated case report forms, databases, and edit checks for a small phase 1 trial from 9 weeks to 5 weeks.
Harnessing the Power of Healthcare Data: Are We There YetHealth Catalyst
What can healthcare learn from Formula One racing? According to Dr. Sadiqa Mahmood, SVP of medical affairs and life sciences for Health Catalyst, race support teams leverage about 30TB of baseline data to create a digital twin of the car, track, and racer for simulation models that drive decisions at each race. Applied in the healthcare setting, a digital twin can help clinicians better understand each patient and their health conditions and circumstances in real time and make comprehensive, informed care decisions. But for the healthcare digital twin to happen, the industry must move away from data silos and towards a digital learning healthcare ecosystem.
How life sciences can win with blockchainToni Borges
The IBM Institute for Business Value surveyed 205 life sciences executives in 18 countries. The study, conducted in collaboration with the Economist Intelligence Unit (EIU), included chief financial officers (CFOs), chief technology officers (CTOs) and chief information officers (CIOs). Those participating had to meet specific criteria: they were either working with — or planning to work with — blockchains in the next 12 months, and they needed to be familiar with the blockchain strategies of their organizations.
Smartphones: When is the first and last time you check yours?ReportLinker.com
Nearly half (46%) of Americans say they check their smartphones as soon as they wake up, while they’re still in bed, according to ReportLinker’s survey results. This is especially true of Millennials, 66% of whom say it’s the first thing they do before getting out of bed.
75% of Ameircans say they keep their smartphones active all day and night, and a staggering 83% of Millennials say they do.
In fact, disconnecting can be hard. More than half of Americans say their last check is right before bed – and 13% say they disconnect only after they’ve gotten into bed for the night. Even after they fall asleep, about 10% say they’ll wake up and check it during the night.
Interview Co-Founder ReportLinker and Findout, Benjamin CarpanoReportLinker.com
ReportLinker and Findout use data analytics technologies to aggregate and normalize data from a wide range of sources to help researchers and analysts find relevant information more efficiently. The companies' core competency lies in both search and data analytics capabilities. Their natural language processing platform analyzes millions of documents daily to extract and structure concepts, relationships, and sentiments to improve users' productivity. Open data initiatives have helped the businesses by providing more content to incorporate, though most value comes from backend processing rather than raw data access. The companies aim to continue enhancing data discovery and contextualization of results.
This graphic shows Samsung's customers are still loyal: 86% of Samsung Customers would consider Samsung next time they upgrade their smartphone. More info on reportlinker.com/inisght
This document provides a summary of a report on the European branded coffee shop market in 23 countries. Some key points:
- It examines the size and growth of the branded coffee shop market in each country from 2009-2015. Several countries like Poland and Spain saw strong growth over 10% in 2011-2012.
- Market leaders like Starbucks, Costa Coffee and Coffee Fellows are profiled for each country along with operating statistics and strategies. Consumer trends toward convenience and sustainability are also discussed.
- Challenges facing the industry like economic uncertainty and high rents are analyzed. Success factors include quality coffee, food offerings and a strong brand. The growth potential of each market is evaluated based on GDP per capita and existing
Allegra's definitive annual study on the UK branded coffee shop market is now available; with insight from over 25,000 consumers the report provides an authoritative view of the market.Drawing on more than 12 years in-depth research, it is considered to be the bible of the coffee sector.KEY AREAS COVERED' Market size and growth projections for the total UK market' Impact of recent economic downturn on trading performance' Key player profiles, including financial performance, pricing analysis and forecasts' Importance of ethical and sustainability issues' Key success factors and market trends' Opportunities and challenges for suppliers' Consumer coffee consumption patterns' Consumer brand awareness and perceptions of key players' Differences between customer demographics, including age, gender, occupation and location by the reportSOURCE OF INFORMATION' Interviews with CEOs, managing directors, senior managers and store managers of major industry players, including:' leading UK coffee and food-focused chains' major coffee roasters and key equipment suppliers' non-specialist players including department stores, supermarkets, bookstores' leading property companies, letting agents and landlords' local authorities' Online surveys with UK coffee shop visitors' Desk research including: News articles and trade press, the Internet and company websites,industry associations, published accounts, data supplied by operators' In-store observations and analysis
Wireless Infrastructure: Market Shares, Strategies, and Forecasts, Worldwide,...ReportLinker.com
WinterGreen Research announces that it has published a new study Wireless Infrastructure: Market Shares, Strategy, and Forecasts, Worldwide, 2013 to 2019. Next generation mission critical systems are leveraging new technology. The 2013 study has 554 pages, 245 tables and figures. Worldwide Wireless Infrastructure markets are poised to achieve significant growth as Building out core networks and backhaul for smart phones.A smart phone is not very smart if the infrastructure can't support its applications. In response to the high growth smart phone markets, wireless infrastructure promises to grow dramatically in the near term.. Wireless Infrastructure technologies include WiMax, LTE, 4G and HSPA. These technologies are driving much higher capacity from the base station back to the fiber core. Fiber core is putting extreme pressure on provider's infrastructure and backhaul networks.WinterGreen Research predicts that the dramatic growth of wireless infrastructure is based on the growth of smart phones to a one trillion market by 2019, serving an installed base of 8.5 billion, many people having more than one smart phone. Wireless infrastructure markets at $58 billion in 2012 will be $163 billion by 2019, new markets evolved because of the value that apps provide to smart phones, mobile devices, tablets, and the Internet of things.According to Susan Eustis, lead author of the study, 'Wireless Infrastructure is being installed to upgrade core networks and upgrade backhaul and base stations to make systems more modern. Infrastructure for the Internet and for smart mobile devices creates demand for more sophisticated web development and web applications that in turn depend on more sophisticated infrastructure. Everything is going mobile. This evolution is driven by mobile smart phones and tablets that provide universal connectivity. Modern systems represent a significant aspect of Internet market evolution.'The proportions of wireless infrastructure market industry segments are expected to remain much as they are, with the small cells and femtocells achieving strong growth on the access side, the core infrastructure must be upgraded to support the added backhaul backbone infrastructure. Wireless apps are expected to achieve $37 trillion revenue by 2019. This unbelievable growth occurs as the Internet is expanded to implement the interconnection of everything.Digital devices proliferate, machine to machine capabilities vastly expand instrumentation. The digital devices become the engine of a world economy, with apps collecting pennies a day for millions of apps from 8.5 billion people with smart phones by 2019.
This document is a fax order form for reports from ReportLinker, which provides industry reports, company profiles, and market statistics. It contains fields for customers to provide contact and billing information as well as select a payment method of credit card, wire transfer, or check in order to place an order for reports. The form directs customers to fax the completed form back to ReportLinker offices in either Europe, the Middle East, and Africa or Asia, Oceania, and America depending on location.
This document is a fax order form for industry reports and company profiles from ReportLinker. It contains fields for customers to provide their contact and shipping information as well as payment details including credit card number, expiration date, and CVV. The form also lists ReportLinker's fax numbers for customers in different regions to submit their orders.
This very short document contains a single word - "TEST" - with no other context provided. It is not possible to provide a meaningful summary in 3 sentences or less given the extremely limited information.
Global Electric Resistance Welded Pipes IndustryReportLinker.com
This report analyzes the worldwide markets for Electric Resistance Welded Pipes in Thousand Tons by the following Product Segments: Mechanical Steel Tubing, Structural Tubing, Structural Steel Pipes, Pressure Tubing, Standard Pipes, Oil Country Tubular Goods, and Line Pipes. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 181 companies including many key and niche players such as Al Jazeera Steel Products Company SAOG, Arabian Pipes Company, ArcelorMittal SA, ERW Pipes Portfolio of ArcelorMittal ChelPipe, Choo Bee Metal Industries Berhad, EVRAZ North America, JFE Steel Corporation, Maharashtra Seamless Limited, Melewar Industrial Group Berhad, Nippon Steel & Sumitomo Metal Corporation, Northwest Pipe Company, OAO TMK, TMK IPSCO, PT Bakrie Pipe Industries, Salzgitter Mannesmann Line Pipe GmbH, Tata Steel Europe, Techint Group SpA, Tenaris S.A., TenarisSiderca, Ternium S.A., United States Steel Corporation, United Metallurgical Company /OMK, Welspun Corp Ltd., Wheatland Tube Company, and Select Products of Wheatland Tube Company. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
This report analyzes the worldwide markets for Wireless Gaming in US$ Million by the following Product Segments: Messaging Based Wireless Gaming, Browser/Web Based Wireless Gaming, and Downloadable Wireless Gaming. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. The report profiles 90 companies including many key and niche players such as Blockdot, Inc., DeNA Co., Ltd., Electronic Arts, Inc., Gameloft SA,GAMEVIL, GREE International, Inc., Glu Mobile Inc., GigaMedia Limited, HandyGames, I-play, Itsmy
Hyperalgesia Global Clinical Trials Review, H1, 2013ReportLinker.com
Hyperalgesia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Hyperalgesia Global Clinical Trials Review, H1, 2013" provides data on the Hyperalgesia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hyperalgesia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hyperalgesia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Genital Herpes Global Clinical Trials Review, H1, 2013ReportLinker.com
Genital Herpes Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Genital Herpes Global Clinical Trials Review, H1, 2013" provides data on the Genital Herpes clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Genital Herpes. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Genital Herpes. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
The Future of Direct Communications Technologies and Proximity-based Applicat...ReportLinker.com
Overview: There are a number of technologies that may be deployed that all provide the ability for devices to "discover" one another, although over different distances ranging from centimeters (Near Field Communications), to meters (Bluetooth), to 10s of meters (Wi-Fi). They also all provide the ability for the devices to communicate directly with one another without a centralized network. Some of these use direct communication as their primary mode of communication e.g. NFC or RFID. Others are more traditional networks which provide direct communication ability as an adjunct to their primary network functions e.g. LTE-Direct or Wi-Fi Direct. Most of the short-term drivers for proximity-based services will be mobile advertising and social networking, especially friend-finder services or dating services, and gaming. In the longer term, other applications will come into play within the scope of the so called Internet of Things. The challenge and opportunity for network operators will be to develop new user scenarios and even new business models to generate revenues from these services. This research uncovers opportunities that will be both beneficial and disruptive to the existing ecosystem and value chain. This research is must reading for any company that is considering offerings within proximity and direct communications and any company that wants to stay ahead of the crowd in terms of preparation for these disruptive technologies. Target Audience: ' Mobile network operators' Industry verticals of all types' Wireless device manufacturers' Network infrastructure companies' Advertising agencies, brands, and merchants' Social networks, advertising, and content providers' Proximity, location, and direct communications vendors Key Report Benefits: ' Market forecasts for each significant technology/solution approach' Recognize the upcoming role and importance of LTE Direct compared to other solutions' Analysis of the major vendors focused on proximity and direct communications solutions' Understand the relationship between proximity, direct communications and the Internet of Things' Understand the technical and business-related differences between proximity/presence and location' Identify each of the major technologies/solutions for proximity detection, location determination, and direct communications' Evaluation of the market for major applications including public safety, social networking, advertising, the Internet of Things, and general location services Select Companies in Report: ' 3M Company' Alcatel-Lucent' iSIGN' LG' Nokia' Samsung' Qualcomm' Verizon Wireless
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...ReportLinker.com
This new 970-page comprehensive five-country report from Venture Planning Group is designed to help current suppliers and potential market entrants identify and evaluate the major business opportunities emerging in the European molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of and cost-effective automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years.
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...ReportLinker.com
This document provides a summary and table of contents for a 900-page report analyzing the clinical chemistry and immunodiagnostic markets in five major European countries. The report explores trends, evaluates competitors, and identifies opportunities in these evolving markets. It contains estimates of test volumes, sales forecasts by category and country, and competitive profiles of leading suppliers.
Bradycardia Global Clinical Trials Review, H1, 2013ReportLinker.com
Bradycardia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Bradycardia Global Clinical Trials Review, H1, 2013" provides data on the Bradycardia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bradycardia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bradycardia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013" provides data on the Acid Indigestion / Heartburn/ Pyrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acid Indigestion / Heartburn/ Pyrosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acid Indigestion / Heartburn/ Pyrosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
This document is a report on the China iron ore mining industry in 2013. It provides an overview of the industry, including its definition and development history. It analyzes the macroeconomic environment and discusses factors like policy, upstream/downstream industries. It also examines the international and domestic markets. Key data on the industry from 2008-2012 is presented, including numbers of enterprises, employees, assets, output, sales, profits and trade. The competitive landscape and strategies of major companies are evaluated. The report concludes with discussions of development trends, investment environment and new technologies in the industry.
1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Lifesciences IT - 2011 Yearbook
Published on June 2011
Report Summary
Lifesciences IT - 2011 Yearbook
Summary
GBI Research's research, 'Lifesciences IT - 2011 Yearbook" provides key data, information and analysis on Lifesciences IT that is
being implemented by pharmaceutical companies. GBI Research expects that information technology (IT) in the lifesciences industry
will become a trendsetter, helping pharmaceutical companies mitigate current and evolving industry challenges. IT solutions utilized in
the value chain of pharmaceutical companies help them to operate effectively and efficiently. GBI expects an increase in the adoption
of IT by pharmaceutical companies looking to remain competitive in the market place.
The Lifesciences industry is pressurized by various challenges such as declining Return on Investment (ROI) on R&D investments,
entry of generics and layoffs. These factors are responsible for the lifesciences companies to invest in information technology
solutions. Pharmaceutical companies have found that experimental techniques are costly, time-consuming, and involve the use of
large numbers of animals for testing and are adapting to computerized combinatorial chemistry applications. Pharmaceutical
Companies are increasingly adopting e-clinical trial solutions in the drug development phase. Cutting down clinical trial cost is the
driving motivation for the adoption of e-clinical trial solutions. Services offered by IT companies in clinical data management are costly
but have been proved to save cost for the companies in the long run. CTMS and EDC will attract the highest investments in the future
followed by data mining, electronic submission tools and RFID. Outsourcing helps a pharmaceutical company to reduce costs by
30-35% and this is one of the main reasons why pharmaceutical companies outsource non-core R&D operational work to IT
companies. When selecting a country to outsource clinical data management work, building the required competencies to tackle client
requirements has gained a higher importance than the cost advantage it provides. The predictive analytics helps a company view
beyond the sales volume in to real time prescribing patterns, as a behavior of continuum. This also helps the company to follow the
evolving niche buster model. Many pharmaceutical companies have increased satisfaction levels from their customers in 2008. In
2004, 50% of the physicians were satisfied on the current number of calls. However, satisfaction levels have increased in 2008 with
more than 57% of the physicians in the US satisfied with the current number of calls. The increase in satisfaction levels was directly
proportional to the decrease of sales force in the US.
It is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by
GBI Research's team of industry experts.
Scope
The scope of this report includes -
- Analysis of the leading segments in the Lifesciences IT market
- Key drivers and barriers that have a significant impact on the Lifesciences IT market.
- Competitive benchmarking of leading companies in the market.
- Key M&A activities and strategic partnership deals that have taken place in 2009.
- Inputs for customized IT solution based on business situation.
Reasons to buy
Lifesciences IT - 2011 Yearbook (From Slideshare) Page 1/8
2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
The report will enhance your decision making capability. It will provide you with -
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading segments poised for strong growth.
- Device better strategies through the understanding of key drivers and barriers in the market.
- Develop key strategic initiatives by understanding the key focus of leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
Table of Content
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 7
2 Lifesciences IT - 2011 Yearbook: Introduction 9
2.1 GBI Research Report Guidance 9
3 Lifesciences IT - 2011 Yearbook: The Need for Information Technology in Lifesciences Industry 10
3.1 Declining ROI on R&D Investment is Among the Biggest Concerns in the Current Pharmaceutical Industry 10
3.1.1 R&D Costs Increase against Revenue Growth for the Top 10 Pharma Companies 12
3.2 Generic Competition and Increasing Number of Patent Challenges 13
3.3 Layoff in the Pharmaceutical Companies 15
3.4 Shrinking Field Force Model 16
4 Lifesciences IT - 2011 Yearbook: Information Technology in Drug Discovery 17
4.1 Drug Discovery Value Chain 17
4.1.1 Target Discovery 17
4.1.2 Target Validation 17
4.1.3 Lead Identification 17
4.1.4 Lead Optimization 17
4.1.5 Preclinical Testing 17
4.2 IT in Drug Discovery Value Chain 17
4.3 Computerized Combinatorial Chemistry and 3D Molecular Modeling 18
4.3.1 Overview 18
4.3.2 Service Providers 19
4.3.3 Case Studies 20
4.4 Molecular Bioimaging 21
4.4.1 Overview 21
4.4.2 Service Providers 21
4.4.3 Case Study 21
4.5 Omics-Technology and Bioinformatics 22
4.5.1 Overview 22
4.5.2 Service Providers 22
4.5.3 Case Study 23
4.6 High-Throughput Screening (HTS) 24
4.6.1 Overview 24
4.6.2 Case Study 24
4.7 Database Systems 25
4.7.1 Overview 25
Lifesciences IT - 2011 Yearbook (From Slideshare) Page 2/8
3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
4.7.2 Case Studies 25
4.8 Using Virtual Technology to Reduce R&D Costs and Time 26
4.9 Technology Support Inevitable For Personalized Medicine: The Future Class of Medicines 27
5 Lifesciences IT - 2011 Yearbook: Information Technology in Drug Development 28
5.1 Overview 28
5.2 Electronic Data Capture (EDC) 29
5.2.1 Cost Saving Scenario in EDC 30
5.2.2 Cost Saving Scenario for Phase I and Phase II Trial 32
5.2.3 SaaS based EDC 33
5.2.4 Case Studies 34
5.3 Electronic Patient Report Outcome System (ePRO) 35
5.3.1 Cost Saving Scenario with eDiaries 36
5.4 Interactive Voice Response Systems (IVRS) 37
5.4.1 Case Studies 37
5.5 Clinical Data Management Systems (CDMS) 39
5.6 Clinical Trial Supply Chain Management System 39
5.6.1 Case Studies 41
5.7 Radio Frequency Identification Tag Architectures 42
5.7.1 RFID IT Architecture 42
5.8 Analysis and Reporting Tools 43
5.8.1 Analysis and Reporting Solutions 43
5.8.2 OnDemand Tools in Analysis and Reporting 43
5.8.3 Clinical Research Intelligence 43
5.8.4 Case Studies 44
5.9 Market Drivers 46
5.9.1 Cutting Down Clinical Trial Cost is the Driving Motivation for the Adoption of eClinical Trial Solutions 46
5.9.2 Improved Data Standardization Increases Adoption of IT Solutions 47
5.9.3 Adaptive Clinical Trials are Preferred by Large Biopharmaceutical Companies 48
5.9.4 Increasing Phase III and Phase II Trials escalates eClinical Solution Adoption 49
5.10 Market Trends 50
5.10.1 Clinical Trial Spending is Increasing at a Faster Rate 50
5.10.2 Electronic Data Capture will Witness High Investments for the Next Five years 51
5.11 Adoption Trends 52
5.11.1 Outsourcing of Clinical Data Management 54
5.11.2 Individual Project Outsourcing Model 55
5.11.3 Full Time Equivalent Model 55
5.11.4 Functional Service Provider Model 55
5.11.5 The Need for Outsourcing 55
5.11.6 A Full Time Equivalent Model Service Provider 56
5.11.7 Outsourcing to India 57
5.11.8 Cost of Setting up a Clinical Data Management Setup in India 58
5.11.9 Case Studies 59
5.12 CDISC Standards & Compliance 60
5.12.1 SDTM 60
5.12.2 ADaM 60
5.12.3 ODM 60
5.12.4 LAB 61
5.12.5 CRT-DDS 61
Lifesciences IT - 2011 Yearbook (From Slideshare) Page 3/8
4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
5.12.6 Protocol standard 61
5.12.7 CDISC Sponsored studies save time and costs 61
5.13 Competitive Benchmarking by Solution Offerings 62
5.14 e-Clinical Trial Solutions - Company Profiles 64
5.14.1 KIKA Medical 64
5.14.2 Omnicomm Systems 64
5.14.3 eResearch Technology 64
5.14.4 Prelude Dynamics 64
5.14.5 Clinipace 64
5.14.6 Phase Forward 65
5.14.7 Perceptive Informatics 65
5.14.8 Clinplus 65
5.14.9 Oracle 65
5.14.10 SAS 65
5.15 Pharmacovigilance 66
5.15.1 Pharmacovigilance in Different Countries 66
6 Lifesciences IT - 2011 Yearbook: Information Technology in Manufacturing & Supply Chain 67
6.1.1 E-Pedigree Solutions 67
6.1.2 Track and Trace Solutions 69
6.1.3 Product Callback Management 70
6.1.4 Authentication of Drugs in the Supply Chain 70
6.1.5 Inventory Management 70
6.1.6 Sample Distribution Management 71
6.1.7 Clinical Trial Solutions 71
7 Lifesciences IT - 2011 Yearbook: Information Technology in Sales & Marketing 72
7.1 CRM 72
7.2 Sales Force Automation 72
7.2.1 Pharma CRM Vendors 72
7.3 Closed Loop Marketing 73
7.3.1 Benefits for Sales & Physicians 74
7.3.2 Benefits for Analytics 74
7.3.3 Benefits for Legal & Regulatory Departments 74
7.3.4 Benefits for Marketing 74
7.3.5 Case Studies 74
7.4 Examining Strategies 78
7.4.1 Promotional Response Model 79
7.4.2 Closed Loop Marketing Vendors 80
7.5 Sales Force Effectiveness Dashboards 80
7.6 New Sales Strategies Implemented 81
7.7 The Future Strategies to be Implemented 82
7.8 Predictive Modeling in Sales & Marketing 85
7.8.1 Case Studies 88
7.9 Key Opinion Leaders Management 88
7.9.1 Key Opinion Leaders in the Pharmaceutical Industry 88
8 Lifesciences IT - 2011 Yearbook: Appendix 90
8.1 Market Definitions 90
8.2 Abbreviations 90
8.3 Research Methodology 91
Lifesciences IT - 2011 Yearbook (From Slideshare) Page 4/8
5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
8.3.1 Coverage 91
8.3.2 Secondary Research 91
8.3.3 Primary Research 91
8.3.4 Expert Panel Validation 92
8.4 Contact Us 92
8.5 Disclaimer 92
8.6 Sources 92
1.1 List of Tables
Table 1: Lifesciences IT - 2011 Yearbook, Pharmaceutical and Biotech R&D Expenditure ($bn) vs. Number of NME/BLA Approvals,
The US, 1995'2009 11
Table 2: Lifesciences IT - 2011 Yearbook, Comparison of CAGR of R&D Expenditure v Turnover for the Top Ten Pharmaceutical
Companies in 2009, 2004'2009 12
Table 3: Lifesciences IT - 2011 Yearbook, Phase I-II Cost Saving Scenario by Adopting EDC , 2009 32
Table 4: Lifesciences IT - 2011 Yearbook, Data Management Set Up Cost in India, 2009 58
Table 5: Lifesciences IT - 2011 Yearbook, CDISC Sponsored Studies, 2009 61
Table 6: Lifesciences IT - 2011 Yearbook, Global, Competitive Benchmarking by Solutions Offering, 2009 62
1.2 List of Figures
Figure 1: Lifesciences IT - 2011 Yearbook, Pharmaceutical and Biotech R&D Expenditure ($bn) vs. Number of NME/BLA Approvals,
the US, 1995'2009 10
Figure 2: Lifesciences IT - 2011 Yearbook, Comparison of CAGR of R&D Expenditure v Turnover for the Top Ten Pharmaceutical
Companies in 2009, 2004'2009 12
Figure 3: Lifesciences IT - 2011 Yearbook, Results Breakdown of Patent Challenges, The US, 2001'2008 14
Figure 4: Lifesciences IT - 2011 Yearbook, Pharmaceutical Industry, Global, Layoffs by Pharmaceutical Companies, 2009 15
Figure 5: Lifesciences IT - 2011 Yearbook, Pharmaceutical Industry, Global, Sales Force Layoffs, 2007-2009 16
Figure 6: Lifesciences IT - 2011 Yearbook, Service Providers in Combinatorial Chemistry and 3D Molecular Modeling 20
Figure 7: Lifesciences IT - 2011 Yearbook, Service Providers of Omics Technology and Bioinformatics 23
Figure 8: Lifesciences IT - 2011 Yearbook, Potential of Genomic Sequencing in Personalized Medicine, ICGC Scientists Statement,
April 2010 27
Figure 9: Lifesciences IT - 2011 Yearbook, Global, Electronic Data Capture through e-CRF, 2009 29
Figure 10: Lifesciences IT - 2011 Yearbook, EDC System- Cost Saving Scenario, 2009 30
Figure 11: Lifesciences IT - 2011 Yearbook, Data Quality Gap, 2009 31
Figure 12: Lifesciences IT - 2011 Yearbook, SaaS based EDC System, 2009 33
Figure 13:Lifesciences IT - 2011 Yearbook, EDC Cost Saving in Clinical Trials ' Therapy Wise, 2009 34
Figure 14: Lifesciences IT - 2011 Yearbook, Cost Saving Scenario of ePRO Solutions, 2009 36
Figure 15: Lifesciences IT - 2011 Yearbook, Case Study of ePRO Solutions, 2009 36
Figure 16: Lifesciences IT - 2011 Yearbook, Integration of IVR with other Systems, 2009 37
Figure 17: Lifesciences IT - 2011 Yearbook, Clinical Data Management Flow, 2009 39
Figure 18: Lifesciences IT - 2011 Yearbook, Clinical Trial Supply Management System, 2009 40
Figure 19: Lifesciences IT - 2011 Yearbook, RFID Technologies in Clinical Trials, 2009 42
Figure 20: Lifesciences IT - 2011 Yearbook, Cost Saving Scenario of a Predictive Modeling Solution, 2009 45
Figure 21: Lifesciences IT - 2011 Yearbook, Cutting Down Clinical Trial Cost is a High Priority Task for Pharmaceutical Companies-
Impact Analysis, 2009 46
Figure 22: Lifesciences IT - 2011 Yearbook, Research and Development Spending Split by Phases ' Impact Analysis 47
Figure 23: Lifesciences IT - 2011 Yearbook, Adaptive Clinical Trials are Preferred by Large Biopharmaceutical Companies - Impact
Analysis, 2009 48
Lifesciences IT - 2011 Yearbook (From Slideshare) Page 5/8
6. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Figure 24: Lifesciences IT - 2011 Yearbook, Increasing Phase III and phase II trials escalates eClinical Solution Adoption ' Impact
Analysis, 2009 49
Figure 25: Lifesciences IT - 2011 Yearbook, Research and Development Spending Split by Phases ' Impact Analysis, 2009 50
Figure 26: Lifesciences IT - 2011 Yearbook, Investment Trends in Future eClinical Trial Solutions 51
Figure 27: Lifesciences IT - 2011 Yearbook, CTMS ' Technology Adoption, 2009 52
Figure 28: Lifesciences IT - 2011 Yearbook, Investigator Portal ' Technology Adoption, 2009 52
Figure 29: Lifesciences IT - 2011 Yearbook, System Integration ' Technology Adoption, 2009 53
Figure 30: Lifesciences IT - 2011 Yearbook, ePRO Solutions ' Technology Adoption, 2009 53
Figure 31: Lifesciences IT - 2011 Yearbook, IVRS Solutions ' Technology Adoption, 2009 54
Figure 32: Lifesciences IT - 2011 Yearbook, Factors Impacting Clinical Data Management Outsourcing, 2009 55
Figure 33: Lifesciences IT - 2011 Yearbook, End-to-End Services Offered by Large IT Vendors , 2009 56
Figure 34: Lifesciences IT - 2011 Yearbook, Supply Chain in Clinical Trials , 2009 57
Figure 35: Lifesciences IT - 2011 Yearbook, e-Pedigree in a Pharmaceutical Supply Chain 67
Figure 36: Lifesciences IT - 2011 Yearbook, Paper Based Pedigree in a Pharmaceutical Supply Chain 68
Figure 37: Lifesciences IT - 2011 Yearbook, Information Flow in Track-and-Trace Applications 69
Figure 38: Lifesciences IT - 2011 Yearbook, CLM Enabled Commercial Organization 73
Figure 39: Lifesciences IT - 2011 Yearbook, Wyeth's Target Selection Model 75
Figure 40: Lifesciences IT - 2011 Yearbook, Wyeth's Segmentation Model 75
Figure 41: Lifesciences IT - 2011 Yearbook, Benefits of CLM for Wyeth 76
Figure 42: Lifesciences IT - 2011 Yearbook, Customer Response Framework for CLM 76
Figure 43: Lifesciences IT - 2011 Yearbook, Customer Response Success Rate for CLM 77
Figure 44: Lifesciences IT - 2011 Yearbook, Wyeth and its CLM Process 77
Figure 45: Lifesciences IT - 2011 Yearbook, Sales Index vs. Sales Strategy 78
Figure 46: Lifesciences IT - 2011 Yearbook, Promotional Response Model 79
Figure 47: Lifesciences IT - 2011 Yearbook, Promotional Response Model on Sales 79
Figure 48: Lifesciences IT - 2011 Yearbook, Global, Implemented Sales Strategies in Pharmaceutical Companies, %, 81
Figure 49: Lifesciences IT - 2011 Yearbook, Global, Sales Strategies to be Implemented in Future, %, 82
Figure 50: Lifesciences IT - 2011 Yearbook, Physician Satisfaction Vs. Decrease in the Sales Force, The US, 2009 83
Figure 51: Lifesciences IT - 2011 Yearbook, Traditional Outsourcing Applications 84
Figure 52: Lifesciences IT - 2011 Yearbook, Modern Outsourcing Applications 85
Figure 53: Lifesciences IT - 2011 Yearbook, Predictive Modeling Data Integration 86
Figure 54: Lifesciences IT - 2011 Yearbook, Predictive Modeling 87
Figure 55: Lifesciences IT - 2011 Yearbook, Predictive Modeling Process 87
Figure 56: Lifesciences IT - 2011 Yearbook, KOL Strategy 89
Companies Mentioned
KIKA Medical
Omnicomm Systems
eResearch Technology
Prelude Dynamics
Clinipace
Phase Forward
Perceptive Informatics
Clinplus
Oracle
SAS
Lifesciences IT - 2011 Yearbook (From Slideshare) Page 6/8
7. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Lifesciences IT - 2011 Yearbook
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 3 500.00 Quantity: _____
Site License--USD 7 000.00 Quantity: _____
Corporate License--USD 10 500.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Lifesciences IT - 2011 Yearbook (From Slideshare) Page 7/8
8. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Lifesciences IT - 2011 Yearbook (From Slideshare) Page 8/8